Progress in human tumour immunology and immunotherapy

By S. Rosenberg. Nature, 2001

1,424 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/b11a6cfb6bfd1dc2debcf309d81872bfac7db834

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Metastasis: a question of life or death (2006, background): “, as exemplified by the development of interleukin-2 ( IL-2 ) treatment in patients with metastatic melanoma and kidney cance”
Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 (2002, background): “This may partly explain the poor clinical response to cancer vaccines even after measurable postvaccination increases in tumorspecific CTLs (14).”
Adoptive immunotherapy for cancer: building on success (2006, background): “CD8 + T cells have been identified as potent effectors of the adaptive antitumour immune respons”
NetPath: a public resource of curated signal transduction pathways (2010, background): “IL-2 clinically has anti-cancer effects [35] as well as utility in supporting T cell numbers in HIV/AIDS [36].”
The Abundant NK Cells in Human Secondary Lymphoid Tissues Require Activation to Express Killer Cell Ig-Like Receptors and Become Cytolytic1 (2004, background): “This could partially explain the beneficial effects observed in some patients treated with rIL-2 for advanced cancers (31).”
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 (2003, background): “19z1 + T cells persist in vivo and travel to bone marrow To analyze the role of CD80 and IL-15, we compared the therapeutic effect of 19z1 + T cells expanded in their presence with that of 19z1 + T cells stimulated with OKT3, an antibody against CD3, and high-dose (500 U/ml) IL-2, a common p”
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007, background): “’’(5) It is now known that the tumor-bearing host can mount T-cell responses to numerous tumor-associated antigens that can either be tissue differentiation antigens, overexpressed normal self proteins, or tumor-associated mutated proteins.(6) Despite the presence of numerous immunogenic targets on ”
Cancer immunotherapy: moving beyond current vaccines (2004, background): “dtd" [ ]> We now know the molecular identities of many tumor-associated antigens, and this knowledge has provided a major stimulus for the development of new immunotherapies for the treatment of patients with solid cancer”
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (2005, background): “Immunotherapeutic and vaccine approaches, such as genetically modified cancer cells, tumor antigen vaccine, and costimulation, could often elicit T-cell responses in experimental animals and in cancer patients (1, 2).”
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells (2005, background): “infiltrating lymphocytes (54) isolated from patients.”
Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1 (2004, background): “ImC may be responsible for the failure of T cells from tumor-bearing hosts to effectively recognize and eliminate tumor cells in an Ag-specific manner, thus allowing the tumor to escape from immune system control (13, 14).”